Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$65.68 USD

65.68
3,456,884

-1.42 (-2.12%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

DexCom (DXCM) Launches Latest CGM Sensor ONE in France

by Zacks Equity Research

DexCom's (DXCM) latest CGM sensor, DexCom ONE, secures reimbursement coverage in France, bringing the real-time CGM sensor to half a million diabetes patients in the country.

Here's Why You Should Retain DexCom (DXCM) Stock for Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed the most recent trading day at $105.22, moving +0.34% from the previous trading session.

DexCom (DXCM) Rises 7% in One Week: What's Driving It?

by Zacks Equity Research

DexCom's (DXCM) shares have rallied nearly 7% over the past week, presumably on positive outlook for its CGM devices amid rising competition.

DexCom (DXCM) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed the most recent trading day at $104.91, moving -1.84% from the previous trading session.

Strength Seen in DexCom (DXCM): Can Its 6.5% Jump Turn into More Strength?

by Zacks Equity Research

DexCom (DXCM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Why DexCom (DXCM) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

DexCom's (DXCM) G6 CGM Connects With Omnipod 5 AID in Germany

by Zacks Equity Research

DexCom's (DXCM) G6 CGM system and Omnipod 5 AID system can now simplify diabetes management and improve health outcomes in Germany.

DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, DexCom (DXCM) closed at $101.90, marking a +0.91% move from the previous day.

Is Trending Stock DexCom, Inc. (DXCM) a Buy Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to DexCom (DXCM). This makes it worthwhile to examine what the stock has in store.

Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWP

Here's Why You Should Invest in Edward Lifesciences (EW) Now

by Zacks Equity Research

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of a solid foundation for innovative therapies.

Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test

by Zacks Equity Research

Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test.

Is Caribou Biosciences (CRBU) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Caribou Biosciences, Inc. (CRBU) and DexCom (DXCM) have performed compared to their sector so far this year.

Abbott (ABT) EPD Arm Grows, Low Testing Sales Play Spoilsport

by Zacks Equity Research

Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and acquisitions.

Cigna (CI) Unit Ties Up to Offer Digital Health Tool to Clients

by Zacks Equity Research

Cigna's (CI) division, Cigna Healthcare, teams up with Virgin Pulse to make an effective digital health solution available to its clients, who can now improve their well-being.

Syneos Health (SYNH) to Go Private, Reports Q2 Performance

by Zacks Equity Research

Syneos Health (SYNH) announces shareholders' approval for the impending merger and releases second-quarter 2023 financial results.

Medtronic (MDT) Rides on Strong Global Growth, New Launches

by Zacks Equity Research

Medtronic (MDT) is gaining from positive sales momentum with the rollout of its differentiated Hugo robotic system in many international markets.

Accuray (ARAY) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Accuray (ARAY) reports a solid fiscal fourth quarter top line on the back of robust segmental performances.

Avanos (AVNS) Q2 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall second-quarter results reflect soft performances.

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and technological investments.

QuidelOrtho (QDEL) Q2 Earnings Top Estimates, FY23 View Revised

by Zacks Equity Research

Despite solid performances by the Labs segment and Other region, QuidelOrtho (QDEL) reports soft overall top-line results in second-quarter 2023.

Masimo (MASI) Q2 Earnings Lag Estimates, Margins Rise

by Zacks Equity Research

Despite strength in Hearables category, Masimo's (MASI) overall second-quarter results reflect soft performances.

PacBio (PACB) Inks Research Collaboration for Genome Sequencing

by Zacks Equity Research

PacBio (PACB) and GeneDx sign a deal with the University of Washington to study long-read sequencing in rare diseases. The study will use PacBio's Revio system to explore novel variants.